19. (New) A method for predicting the likelihood that an individual will have coronary heart disease, comprising the steps of:

(a) obtaining a nucleic acid sample from an individual to be assessed; and

(b) determining the nucleotide present at the polymorphic site of one or more nucleic acid molecules having a nucleotide sequence comprising SEQ ID NO: 5,

wherein the presence of a nucleotide associated with a greater likelihood of having coronary heart disease indicates that the individual has a greater likelihood of having a cardiovascular disease than if another nucleotide were present at the polymorphic site.

20. (New) The method of Claim 19, wherein thymine is the nucleotide associated with a greater likelihood of having coronary heart disease present at the polymorphic site of SEQ ID NO: 5.

REMARKS

Claims 1-8 have been canceled, Claims 9, 10, 12 and 14 have been amended, and new Claims 16-20 have been added to reflect the elections made in response to the Restriction Requirement. No new matter has been added. Entry of the Claim amendments is respectfully requested.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Lisa M. Treannie

Lisa M. Treannie
Registration No. 41,368
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133
Dated: 8/27/02

MARKED UP VERSION OF AMENDMENTS

Claim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)

9. (Amended) A method of analyzing a nucleic acid sample for [polymorphisms] a polymorphism associated with cardiovascular disease, comprising the steps of:

(a) obtaining a nucleic acid sample from one or more individuals, and

(b) determining the nucleotide occupying [one or more of] the polymorphic site [sites] of [one or more nucleic acid molecules selected from the group consisting of] SEQ ID NO [NOS]: 5 [1-22].

10. (Amended) A method according to Claim 9, wherein a plurality of [the] nucleic acid samples is obtained from a plurality of individuals, and the nucleotide occupying one or more [of the] polymorphic sites is determined in each of the individuals.

12. (Amended) A method for predicting the likelihood that an individual will have a cardiovascular disease, comprising the steps of:

(a) obtaining a nucleic acid sample from an individual to be assessed; and

(b) determining the nucleotide present at [a] the polymorphic site of one or more nucleic acid molecules having a nucleotide sequence comprising [selected from the group consisting of] SEQ ID NO [NOS]: 5 [1-22],

wherein the presence of a nucleotide associated with a lower likelihood of having a cardiovascular disease indicates that the individual has a lower likelihood of having a cardiovascular disease than if another nucleotide [was] were present at the polymorphic site.

14. (Amended) A method for predicting the likelihood that an individual will have a cardiovascular disease, comprising the steps of:

(a) obtaining a nucleic acid sample from an individual to be assessed; and

(b) determining the nucleotide present at [a] the polymorphic site of one or more nucleic acid molecules having a nucleotide sequence comprising [selected from the group consisting of] SEQ ID NO [NOS]: 5 [1-22],

wherein the presence of a nucleotide associated with a greater likelihood of having a cardiovascular disease indicates that the individual has a greater likelihood of having a cardiovascular disease than if another nucleotide [was] were present at the polymorphic site.